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Introduction
Autologous stem cell transplantation (ASCT), high-dose 
chemotherapy followed by hematopoietic stem cell rescue, 
is a widely used therapeutic strategy especially for some 
patients with hematological malignancies such as malignant 
lymphoma or multiple myeloma (MM). Because successful 
ASCT is crucial in these patients for improving overall 
survival [1], collection of a sufficient number of hemato-
poietic stem cells for restoring the bone marrow function 
is very important. Although most hematopoietic stem cells 
are located within the bone marrow, BM harvest is 
accompanied by procedure related risk and relatively lower 
yield. Therefore, the mobilization of hematopoietic stem 
cells by using growth factors such as granulocyte 
colony-stimulating factor (G-CSF) either as a single agent 
or in combination with chemotherapy (chemo-mobilization) 
and the collection of mobilized peripheral blood (PB) 
hematopoietic stem cells are essential processes for using 
the peripheral blood stem cell (PBSC) as a stem cell source. 
However, these classical PBSC mobilization methods fail 
to collect sufficient number of PBSCs in 5–40% of patients 
[1]. Plerixafor is a reversible CXCR4 chemokine receptor 
antagonist and blocks binding of stromal cell-derived factor 
1-alpha, resulting in mobilization of CD34＋ cells to the 
PB. The additional use of plerixafor to G-CSF resulted in 
a significantly higher probability of achieving the optimal 
PBSC targets in patients who failed at least one PBSC 
mobilization attempt [1, 2]. Plerixafor gained Food and Drug 
Administration (FDA) approval in 2008 and has been 
reimbursed from the Korean Health Insurance Review and 
Assessment Service (HIRA) since 2012 in Korea. Its Korean 
reimbursement guideline was expanded in 2015. Plerixafor 
is used for non-Hodgkin lymphoma (NHL) or MM patients 
who failed to collect sufficient number of PBSCs at the 
previous PBSC mobilization attempt in Korea. Therefore, 
the appropriate use of plerixafor would increase the number 
of patients receiving ASCT and improve the overall 
treatment outcomes of these hematological malignancies. 
Herein, we review the current issues in PBSC mobilization 
including the definition of mobilization failure and suggest 
the future perspectives of PBSC mobilization.
Current issues
The generally accepted minimal target PBSC number is 
2×106 CD34＋ cells/kg with an optimal number of 5×106 
CD34＋ cells/kg [1]. Previously, a consensus definition of 
‘mobilization failure’ as a count of ＜2.0×106 CD34＋ cells/kg 
after 3 courses of apheresis was made by the board members 
of the Consortium for Improving Survival of Lymphoma 
in Korea [2]. However, the target number of CD34＋ cells 
should be modified according to the number of ASCT 
because second ASCT is usually recommended in patients 
with MM who have sufficient remission duration after first 
ASCT. In addition, tandem ASCT is still recommended 
especially for the high risk MM patients. Therefore, 
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Table 1. Mobilization outcomes of immediate salvage use of plerixafor.
Underlying disease Mobilization regimen Plerixafor use Failure of mobilization
Veltri L et al. 2015 [7] Lymphoma & MM G-CSF only 36/60 (60%) 2/60 (3.3%)
Micallef IN et al. 2013 [8] Lymphoma & MM G-CSF only 57/98 (58%) 1/98 (1.0%)
Milone G et al. 2014 [9] Lymphoma & MM CTX 4 g/m2 or DHAP+G-CSF 9/102 (8.8%) 4/102 (4.0%)
Abbreviations: CTX, cyclophosphamide; DHAP, dexamethasone, cytosine arabinoside, and cisplatin; G-CSF, granulocyte colony-stimulating 
factor; MM, multiple myeloma.
International Myeloma Working Group suggested that a 
minimum target of 4×106 CD34＋ cells/kg be collected and 
that if feasible an average of 8–10×106 CD34＋ cells/kg be 
collected in the patients with MM [3]. In the previous phase 
3 trials for plerixafor, the primary end point was the 
percentage of patients who collected 5×106 CD34＋ cells/kg 
in ≤4 apheresis days for NHL [4] and 6×106 CD34＋ cells/kg 
in ≤2 apheresis days for MM [5]. Therefore, the previous 
definition of mobilization failure and the guideline for using 
plerixafor should be modified. If collecting for 1 ASCT, 
mobilization failure would be a count of ＜2.0×106 CD34＋ 
cells/kg. On the other hand, if collecting for more than 
1 ASCT, at least a count of ＜4.0×106 CD34＋ cells/kg should 
be a criterion for mobilization failure.
To determine the appropriate date on which to initiate 
PBSCs collection, the serial monitoring of PB CD34＋ cells 
count is essential. Mobilization with G-CSF alone (usually 
at a dose of 10 μg/kg subcutaneously daily) or G-CSF plus 
plerixafor (240 μg/kg) makes peak circulating PB CD34＋ 
cells count between the 4th and 6th days of therapy. Therefore, 
monitoring of PB CD34＋ cells usually begins on either the 
4th or 5th day. For patients with chemo-mobilization, moni-
toring of PB CD34＋ cells usually starts on the 8th–10th days 
after chemotherapy or white blood cell count ＞1.0×109/L 
because the peak timing of PB CD34＋ cells count varies 
according to the specific chemotherapy regimens [1]. In 
addition, pre-apheresis PB CD34＋ cells count monitoring 
is useful for identifying the patients who eventually fail 
to collect a sufficient number of PBSCs. According to the 
previous decision-making algorithm for the use of plerixafor, 
PB CD34＋ cells ＜10/μL for the minimal target PBSC 
number of 2×106 CD34＋ cells/kg and PB CD34＋ cells 
＜20/μL for 4×106 CD34＋ cells/kg would be appropriate 
for the use of plerixafor [1]. Therefore, the serial monitoring 
of PB CD34＋ cell count will be able to select the most 
appropriate date of PBSCs collection and reduce unnecessary 
PBSCs collection attempt. Eventually, we can avoid unne-
cessary use of plerixafor. However, the serial monitoring 
of PB CD34＋ cells count during stem cell mobilization is 
not allowed from the HIRA reimbursement guideline. 
Therefore, these reimbursement policies of HIRA should 
be modified and improved in the future.
Re-mobilization using plerixafor after the failure of first 
PBSC mobilization attempt has been usually recommended 
and reimbursed in Korea for patients who cannot collect 
sufficient number of PBSC for ASCT. After at least 7-day 
rest period, G-CSF plus plerixafor is usually applied for 
re-mobilization. However, it will take a lot of time to collect 
an appropriate number of CD34＋ cells for subsequent ASCT 
and delaying the schedule of ASCT may be related to poor 
treatment outcomes. Therefore, the immediate salvage use 
of plerixafor (just in time plerixafor) for patients with 
suboptimal mobilization according to the PB CD34＋ cells 
count or the apheresis results of the first day of apheresis 
should be considered [6]. The immediate salvage use of 
plerixafor is the additional use of plerixafor during 
mobilization when the PB CD34＋ cells count is ＜10/μL 
for 1 ASCT, and ＜20/μL for more than 1 ASCT. In addition, 
the first-day apheresis yield of ＜1.5×106 CD34＋ cells/kg 
or subsequent day apheresis yield of ＜0.5×106 CD34＋ 
cells/kg also should be indicated for the immediate salvage 
use of plerixafor [6]. The strategy of immediate salvage 
use of plerixafor will increase the rates of successful PBSC 
mobilization, reduce the number of apheresis attempt and 
save the total cost of mobilization [7-9] (Table 1). 
The HIRA reimburses only two doses of plerixafor 
administration per patient in Korea. It was basically because 
the median use of plerixafor was two doses in the previous 
phase 3 trial [4, 5]. However, the plerixafor is continuously 
used until the target number of CD34＋ cells is collected 
and the probability of successfully achieving the target 
number of CD34＋ cells continuously increases after the 
3rd PBSC apheresis using plerixafor [4, 5]. Therefore, the 
limitation on the number of plerixafor usage is inappropriate 
and the guideline should be revised.
Future perspectives
The goals of PBSCs mobilization should be collecting 
sufficient amount of PBSCs, to minimize mobilization 
related morbidities, and to reduce the use of the resources. 
Therefore, appropriate use of plerixafor in patients who 
likely to benefit from ASCT and reduced trials of unne-
cessary PBSCs collection attempt should be the main policies 
of PBSC mobilization. To achieve these goals, the definition 
of mobilization failure should be modified according to the 
number of ASCT. In addition, the serial monitoring of PB 
CD34＋ cells count during stem cell mobilization should 
be allowed. Although plerixafor-based re-mobilization after 
first mobilization failure is widely used, immediate salvage 
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use of plerixafor (just in time plerixafor) for patients with 
suboptimal mobilization should be considered. In the future, 
the pre-emptive use of plerixafor for the first mobilization 
attempt should be applied in patients with predicted poor 
mobilization. The use of plerixafor for the first mobilization 
attempt is also tried because greater numbers of CD34＋ 
cells may provide faster engraftment and, potentially, better 
long-term outcomes. Many new molecules for PBSC 
mobilization such as a high-affinity CXCR4 antagonist and 
a sphingosine-1-phosphate agonist have been under trials 
[10]. Therefore, mobilization failure and poor mobilization 
would not be an essential problem in the near future. 
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